Dermira Inc.’s Phase IIb data for its IL-13 inhibitor lebrikizumab in atopic dermatitis showed efficacy across three dosing regimens, with a profile similar to market leader Dupixent. Now, the company hopes to initiate a Phase III study by year’s end that could set up the therapy with a dosing-convenience advantage compared to Sanofi/Regeneron Pharmaceuticals Inc.’s IL-4/IL-13 receptor antagonist.
Dupixent (dupilumab) became the first biologic approved for atopic dermatitis in 2017, and in its first full year on the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)